BRIEF-Syros receives FDA Orphan drug designation for SY-1425 for treatment of AML

Featured

Markets and Economy

Market Jockey

Germany

Chastened Merkel braces for coalition tussle after vote

Sports

India clinch series with hat-trick of wins against Australia

Pictures Reuters TV

Africa América Latina عربي Argentina Brasil Canada 中国 Deutschland España France India Italia 日本 México РОССИЯ United Kingdom United States

#Regulatory News

August 21, 2017 / 12:10 PM / a month ago

BRIEF-Syros receives FDA Orphan drug designation for SY-1425 for treatment of AML

Reuters Staff

1 Min Read

Aug 21 (Reuters) - Syros Pharmaceuticals Inc

* Syros receives fda orphan drug designation for SY-1425 for treatment of AML

* Syros Pharmaceuticals Inc- ‍look forward to presenting initial clinical data from ongoing Phase 2 clinical trial of SY-1425 in Q4 of this year Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.